Coastline Trust Co Has $14.32 Million Position in Eli Lilly and Company $LLY

Coastline Trust Co reduced its stake in shares of Eli Lilly and Company (NYSE:LLY) by 0.1% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 18,373 shares of the company’s stock after selling 25 shares during the quarter. Eli Lilly and Company comprises 1.6% of Coastline Trust Co’s portfolio, making the stock its 17th biggest position. Coastline Trust Co’s holdings in Eli Lilly and Company were worth $14,322,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. WestEnd Advisors LLC grew its position in shares of Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock worth $26,000 after buying an additional 21 shares during the period. Wealth Preservation Advisors LLC acquired a new position in shares of Eli Lilly and Company during the 1st quarter worth about $27,000. Citizens National Bank Trust Department grew its position in shares of Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock worth $35,000 after buying an additional 27 shares during the period. Financial Gravity Asset Management Inc. acquired a new position in shares of Eli Lilly and Company during the 1st quarter worth about $40,000. Finally, TD Capital Management LLC grew its position in shares of Eli Lilly and Company by 129.2% during the 1st quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after buying an additional 31 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Eli Lilly and Company

In related news, Director Jamere Jackson acquired 200 shares of the company’s stock in a transaction dated Friday, August 8th. The shares were bought at an average price of $639.56 per share, for a total transaction of $127,912.00. Following the purchase, the director directly owned 9,402 shares in the company, valued at approximately $6,013,143.12. This trade represents a 2.17% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO David A. Ricks acquired 1,632 shares of the company’s stock in a transaction dated Tuesday, August 12th. The shares were bought at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the purchase, the chief executive officer owned 546,601 shares in the company, valued at approximately $352,431,926.77. This represents a 0.30% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 4,514 shares of company stock worth $2,894,841. Corporate insiders own 0.13% of the company’s stock.

Analyst Ratings Changes

LLY has been the subject of several research analyst reports. Guggenheim decreased their price objective on Eli Lilly and Company from $942.00 to $875.00 and set a “buy” rating for the company in a research report on Wednesday, August 13th. Daiwa Capital Markets lowered Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price objective for the company. in a research report on Sunday, August 17th. HSBC upgraded Eli Lilly and Company from a “reduce” rating to a “hold” rating and boosted their price objective for the company from $675.00 to $700.00 in a research report on Wednesday, August 27th. Daiwa America lowered Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 17th. Finally, Deutsche Bank Aktiengesellschaft decreased their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a research report on Monday, August 11th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $939.61.

Eli Lilly and Company Trading Up 1.4%

NYSE LLY opened at $724.73 on Friday. The stock has a market capitalization of $685.93 billion, a price-to-earnings ratio of 47.37, a PEG ratio of 1.01 and a beta of 0.47. The stock’s 50 day moving average price is $734.15 and its two-hundred day moving average price is $766.82. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $937.00.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to analysts’ expectations of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business’s quarterly revenue was up 37.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.